Jedd Comiskey, Senior Vice President, Head of Europe, highlights the recent NICE recommendation of LYTENAVA™ (bevacizumab gamma) for the treatment of wet AMD Access the segment here ISELIN, N.J., Jan.

Pravin U. Dugel, MD, Ocular's Executive Chairman, President and CEO, will provide an update regarding the enrollment status ...

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today ...

Updates on commercial insights and readiness plans for sozinibercept in wet AMDOpthea management to present in New York City on Tuesday, January ...

From redness to gradual loss of vision to constant irritation, here are the early warning signs of eye diseases that should ...

The FDA has approved a first-of-its-kind treatment for dry age-related macular degeneration (AMD), a leading cause of blindness in adults over 55.